QUADRATENS, MODEL QT-42

K061799 · Bio-Research Associates, Inc. · GZJ · Aug 28, 2006 · Neurology

Device Facts

Record IDK061799
Device NameQUADRATENS, MODEL QT-42
ApplicantBio-Research Associates, Inc.
Product CodeGZJ · Neurology
Decision DateAug 28, 2006
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 882.5890
Device ClassClass 2
AttributesTherapeutic

Indications for Use

The QuadraTENS Model QT-42 neuromuscular stimulator may be used for the symptomatic relief and management of chronic (long-term) intractable pain and as an adjunctive treatment in the management of post-surgical and post-traumatic acute pain problems.

Device Story

QuadraTENS Model QT-42 is a 2-channel transcutaneous electrical nerve stimulator (TENS) for pain management. Device delivers electrical stimulation via surface electrodes to patient skin. Inputs include user-adjusted amplitude and balance settings; device generates symmetrical bipolar pulses (600 microsecond pulse-width) or burst mode (8 pulses at 800 Hz). Powered by 9V battery; transformer-coupled outputs ensure zero net DC current. Two channels are isolated and staggered to prevent crosstalk. Used by or on order of licensed practitioner. Output provides symptomatic pain relief. Differences from predicate include transition from through-hole to surface-mount PC board components and detachable lead-wires, intended to improve reliability.

Clinical Evidence

Bench testing only. Validation performed for automatic stand-by mode, symmetric bipolar waveform with zero net DC, non-crossover between channel outputs, and constant current output. No clinical data provided.

Technological Characteristics

2-channel TENS device; 9V battery powered. Symmetrical bipolar pulse; 600 microsecond pulse-width; 1 Hz rate (single pulse) or 800 Hz (burst mode). Transformer-coupled outputs; 0-40 mA peak amplitude. Surface-mount PC board; detachable lead-wires; ABS case. Compliant with ISO 9000, ISO 13485, and RoHS. Digital logic for frequency/pulse-width; analog controls for amplitude/balance.

Indications for Use

Indicated for symptomatic relief and management of chronic, intractable pain and adjunctive treatment for post-surgical and post-trauma acute pain.

Regulatory Classification

Identification

A transcutaneous electrical nerve stimulator for pain relief is a device used to apply an electrical current to electrodes on a patient's skin to treat pain.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ page 1:4 K061799 AUG 2 8 2006 # QuadraTENS Model OT-42 510(k) Summary Statement 1. This summary prepared by: John C. Radke (contact person) President/Official Correspondent Revised on August 25, 2006 Submitted by BioResearch Associates, Inc. 9275 N. 49th Street Suite 150 Brown Deer, WI 53223 PH: (414) 357-7525 FX: (414) 357-7545 #### QuadraTENS™ Model QT-42 2. four lead-wires) (a two channel TENS device with ### Transcutaneous Electrical Neural Stimulator and Stimulator Device: stimulator, nerve, transcutaneous, for pain relief Regulation Description: Transcutaneous electrical nerve stimulator for pain relief Regulation Medical Specialty: Neurology Review Panels: Neurology Product Codes: GZJ Submission Type: 510(k) traditional Regulation Number: 21 CFR 882.5890 Device Class: II GMP exempt? [No] ### 3. Legally marketed equivalent devices BioTENSTM 510(k) number = K844618B (TENS) Empi Model 989 510(k) number = K881114 (burst mode feature) 4. The QuadraTENS Model QT-42 is a 2 channel version of the BioTENS with the addition of a burst mode. Like the BioTENS, it is also intended to be used by or on the order of a licensed practitioner. The burst mode has been added specifically because a single stimulus is sometimes insufficient. By adding a second channel, the QuadraTENS Model QT-42 can be applied simultaneously to another separately enervated area on the same patient. ✓ Nite drumm "Dentist". {1}------------------------------------------------ The low frequency stimulation (1.0 Hz rate) of the QuadraTENS Model QT-42, the same as its predecessor BioTENS, is applied to a patient through surface electrodes. The QuadraTENS Model QT-42 is designed and manufactured in compliance with FDA GMP regulations, ISO 9000 and ISO 13485 standards as well as RoHS. The Unit is powered by a single 9 volt battery. It produces a symmetrical bipolar pulse with a factory-set pulse-width of 600 microseconds and a rate of 1 pulse/second. The transformer-coupled outputs, which are equivalent to the both the BioTENS and the EMPI Model 989, apply 0.0 milliamps of net dc current to the patient. Image /page/1/Figure/3 description: The image shows an oscilloscope display with a square wave signal. The vertical scale is set to 5.00V per division, and the horizontal scale is set to 100 microseconds per division. The signal has a frequency of less than 10Hz, and the coupling is set to DC. The bandwidth limit is off at 60MHz, and the probe is set to 1X. Fig. 1. Wave-shape and pulse-width of QuadraTENS Model QT-42 in single pulse mode applied across a 1,000 Ohm load (peak current shown = 15ma) In the burst mode, a fixed train of 8 pulses with a repetition rate of 800 Hz is output once/second. The nominal pulse amplitude is controlled separately for each channel and ranges from 0.0 ma to a maximum of 40 milliamps peak. The 2 channels are isolated from each other and their output pulses are staggered in time to prevent any current from flowing between channels, which results in zero crosstalk. Each channel also includes a balance control that adjusts the amplitudes of the positive and negative half waves differentially. The balance is used to equalize the responses at each electrode site. {2}------------------------------------------------ Image /page/2/Figure/1 description: The image shows an oscilloscope display with a waveform. The display indicates settings such as 'Type Vector', 'Persist Off', and 'Format YT'. The waveform is a periodic signal, and the display shows 'CH1 1.00V' and 'M 1.00ms', with a frequency of '<10Hz'. Image /page/2/Figure/2 description: The image shows the text "Fig. 2. Burst Mode Train of Eight Pulses. (Oscilloscope in 10X mode, 1,000 Ohm load, showing a peak current = 24 milliamps)". The text describes a burst mode train of eight pulses. The oscilloscope is in 10X mode with a 1,000 Ohm load. The peak current is 24 milliamps. ### 5. Intended use statement The QuadraTENS Model QT-42 neuromuscular stimulator may be used for the symptomatic relief and management of chronic (long-term) intractable pain and as an adjunctive treatment in the management of post-surgical and post-traumatic acute pain problems. {3}------------------------------------------------ Page 4/4 6. Since the BioTENS has been functioning successfully for two decades and since we have received very few recommendations for changes, the QuadraTENS Model QT-42 has very few differences in its design. However, there have been changes in the technology of electronics in the past 20 years. Although both devices use digital logic to generate the frequency and pulse-width settings and analog controls for amplitude and balance, differences in construction include: #### BioTENS QuadraTENS Model QT-42 Through-hole PC Board and components Hand assembled and soldered Permanently attached lead-wires Custom-molded ABS case FDA GMP Compliant Surface-mount PC board and components Machine assembled and soldered Detachable "touch-free" lead-wires Ready-made ABS case FDA GMP, ISO 9000/13485/RoHS compliant In our opinion these differences should lead to greater reliability and fewer customer complaints. ### Appendix 1 ### Assessment of performance (non-clinical) | | Design qualification testing was performed for the following purposes: | Completed | |----|------------------------------------------------------------------------|-----------| | 1. | Validation test of automatic stand-by mode for safety | [x] | | 2. | Validation of symmetric bipolar waveform with zero net DC | [x] | | 3. | Validation test of non-crossover between the separate channel outputs | [x] | | 4. | Validation test of constant current outputs | [x] | The results of each test validate that the design meets all specifications, is equivalent to current legally marketed devices and is acceptable for its intended use. {4}------------------------------------------------ Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 ### AUG 2 8 2006 Bio-Research Associates % Mr. John C. Radke President 9275 North 49th Street, Suite 150 Brown Deer, Wisconsin 53223 Re: K061799 Trade Name: QuadraTENS, Model QT-42 Regulation Number: 21 CFR 882.5890 Regulation Name: Transcutaneous Electrical Nerve Stimulator for Pain Relief Regulatory Class: Class II Product Code: GZJ Dated: August 11, 2006 Received: August 14, 2006 Dear Mr. Radke: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {5}------------------------------------------------ Page 2 - Mr. John C. Radke This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Barbara Buchner Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health {6}------------------------------------------------ ## Indications for Use 510(k) Number (if known):_____________________________________________________________________________________________________________________________________________________ Device Name:__QuadraTENS Model QT-42 Indications For Use: QuadraTENS is indicated for the symptomatic relief and management of chronic, intractable pain and adjunctive treatment for post-surgical and post-trauma acute pain. Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Vaybara Buchem ofuxm (Division Sign-Off) Division of General, Restorative. and Neurological Devices Page 1 of 510(k) Number K061799
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...